The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma

Trond Velde Bogsrud, Dimitrios Karantanis, Mark A. Nathan, Brian P. Mullan, Gregory A. Wiseman, Jan Kasperbauer, Carl C. Reading, Trine Björo, Ian D Hay, Val Lowe

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures: This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Results: Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. Conclusion: FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.

Original languageEnglish (US)
Pages (from-to)547-553
Number of pages7
JournalMolecular Imaging and Biology
Volume12
Issue number5
DOIs
StatePublished - Oct 2010

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Calcitonin
Glucose
Medullary Thyroid cancer
Carcinoembryonic Antigen
Disease Progression
Retrospective Studies

Keywords

  • 2-deoxy-2-[18F]fluoro-d-glucose
  • FDG
  • Medullary thyroid carcinoma
  • PET
  • PET/CT
  • Positron emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. / Bogsrud, Trond Velde; Karantanis, Dimitrios; Nathan, Mark A.; Mullan, Brian P.; Wiseman, Gregory A.; Kasperbauer, Jan; Reading, Carl C.; Björo, Trine; Hay, Ian D; Lowe, Val.

In: Molecular Imaging and Biology, Vol. 12, No. 5, 10.2010, p. 547-553.

Research output: Contribution to journalArticle

Bogsrud, Trond Velde ; Karantanis, Dimitrios ; Nathan, Mark A. ; Mullan, Brian P. ; Wiseman, Gregory A. ; Kasperbauer, Jan ; Reading, Carl C. ; Björo, Trine ; Hay, Ian D ; Lowe, Val. / The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. In: Molecular Imaging and Biology. 2010 ; Vol. 12, No. 5. pp. 547-553.
@article{7a6bc647c45241f883fa630690f714c4,
title = "The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma",
abstract = "Purpose: To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures: This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Results: Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. Conclusion: FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.",
keywords = "2-deoxy-2-[18F]fluoro-d-glucose, FDG, Medullary thyroid carcinoma, PET, PET/CT, Positron emission tomography",
author = "Bogsrud, {Trond Velde} and Dimitrios Karantanis and Nathan, {Mark A.} and Mullan, {Brian P.} and Wiseman, {Gregory A.} and Jan Kasperbauer and Reading, {Carl C.} and Trine Bj{\"o}ro and Hay, {Ian D} and Val Lowe",
year = "2010",
month = "10",
doi = "10.1007/s11307-009-0276-2",
language = "English (US)",
volume = "12",
pages = "547--553",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma

AU - Bogsrud, Trond Velde

AU - Karantanis, Dimitrios

AU - Nathan, Mark A.

AU - Mullan, Brian P.

AU - Wiseman, Gregory A.

AU - Kasperbauer, Jan

AU - Reading, Carl C.

AU - Björo, Trine

AU - Hay, Ian D

AU - Lowe, Val

PY - 2010/10

Y1 - 2010/10

N2 - Purpose: To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures: This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Results: Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. Conclusion: FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.

AB - Purpose: To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures: This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Results: Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. Conclusion: FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.

KW - 2-deoxy-2-[18F]fluoro-d-glucose

KW - FDG

KW - Medullary thyroid carcinoma

KW - PET

KW - PET/CT

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=78049336593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049336593&partnerID=8YFLogxK

U2 - 10.1007/s11307-009-0276-2

DO - 10.1007/s11307-009-0276-2

M3 - Article

C2 - 19949985

AN - SCOPUS:78049336593

VL - 12

SP - 547

EP - 553

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 5

ER -